{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders. Responders were those who had complete response and partial response. Clinical endpoints and response criteria (Olsen et al., 2011) for in CTCL (mycosis fungoides and Sezary syndrome) and TCL were used for assessment. Tumor types evaluated included Cutaneous T-cell lymphoma (CTCL) and a part of T-cell lymphoma (TCL).","groups":[{"description":"Participants with CTCL who received study drug in Parts 2 and 3.","id":"OG000","title":"Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL)"},{"description":"Participants with TCL who received study drug and response assessment by Olsen 2011 in Parts 2 and 3.","id":"OG001","title":"Parts 2 and 3: T-cell Lymphoma (TCL)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set included all participants who received at least 1 dose of study treatment. \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)","title":"Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication","type":"SECONDARY","unitOfMeasure":"Participants"}